Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance

Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence

(2020) Sha Zhang et al.   ONCOLOGY REPORTS

Scutellarin suppresses proliferation and promotes apoptosis in A549 lung adenocarcinoma cells via AKT/mTOR/4EBP1 and STAT3 pathways

(2019) Pikun Cao et al.   Thoracic Cancer

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)

(2019) Ying Z. Mazzu et al.   CLINICAL CANCER RESEARCH

Comprehensive immune characterization and T‐cell receptor repertoire heterogeneity of retroperitoneal liposarcoma

(2019) Liang Yan et al.   CANCER SCIENCE

Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction

(2018) Ping Chen et al.   CLINICAL SCIENCE

siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin

(2018) Shuquan Zheng et al.   Molecular Therapy-Nucleic Acids

Did outcomes improve in retroperitoneal sarcoma surgery?

(2018) Ferdinando Carlo Maria Cananzi et al.   SURGICAL ONCOLOGY-OXFORD

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

(2017) Andrew J. Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel chimeric transcript RRM2-c2orf48 promotes metastasis in nasopharyngeal carcinoma

(2017) Ping Han et al.   Cell Death & Disease

Preoperative radiotherapy in the management of retroperitoneal liposarcoma

(2016) B. L. Ecker et al.   BRITISH JOURNAL OF SURGERY

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

(2016) J. R. Infante et al.   CLINICAL CANCER RESEARCH

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

(2016) Mrinal M. Gounder et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity

(2016) Rikke D. Rasmussen et al.   Nature Communications

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib

(2016) Mark A. Dickson et al.   JAMA Oncology

Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma

(2015) Alessandro Gronchi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Targeting Ribonucleotide Reductase M2 and NF- B Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer

(2015) K. N. Shah et al.   MOLECULAR CANCER THERAPEUTICS

Salvianolic acid B protects human endothelial progenitor cells against oxidative stress-mediated dysfunction by modulating Akt/mTOR/4EBP1, p38 MAPK/ATF2, and ERK1/2 signaling pathways

(2014) Yubo Tang et al.   BIOCHEMICAL PHARMACOLOGY

Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer

(2014) N Wang et al.   BRITISH JOURNAL OF CANCER

Pleomorphic liposarcoma: A cytologic study of five cases

(2014) Leslie G. Dodd et al.   DIAGNOSTIC CYTOPATHOLOGY

PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways

(2014) Xiaoxing Xiong et al.   NEUROBIOLOGY OF DISEASE

Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma

(2014) WEI KANG et al.   ONCOLOGY REPORTS

Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance

(2014) Nagireddy Putluri et al.   NEOPLASIA

Liposarcomas: diagnostic pitfalls and new insights

(2013) Angelo P Dei Tos   HISTOPATHOLOGY

Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers

(2012) Xiyong Liu et al.   CLINICAL SCIENCE

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY